Ensign Peak Advisors, Inc Theravance Biopharma, Inc. Transaction History
Ensign Peak Advisors, Inc
- $55.3 Billion
- Q4 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 60,907 shares of TBPH stock, worth $585,316. This represents 0.0% of its overall portfolio holdings.
Number of Shares
60,907
Previous 60,907
-0.0%
Holding current value
$585,316
Previous $490,000
16.94%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding TBPH
# of Institutions
129Shares Held
46.5MCall Options Held
200Put Options Held
1.2K-
Madison Avenue Partners, LP New York, NY9.51MShares$91.4 Million14.29% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$71.7 Million2.02% of portfolio
-
Newtyn Management, LLC New York, NY4.76MShares$45.7 Million9.1% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$36.3 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$26.5 Million2.79% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $642M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...